-
Subject Areas on Research
-
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
-
A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates.
-
A genetically engineered, stem-cell-derived cellular vaccine.
-
A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma.
-
A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
-
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
-
A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.
-
AIDS vaccines.
-
AIDS vaccines: progress and unmet challenges.
-
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.
-
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
-
Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.
-
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
-
Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs.
-
Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens.
-
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.
-
An ethical framework for global vaccine allocation.
-
An innovative approach to induce cross-protective immunity against porcine reproductive and respiratory syndrome virus in the lungs of pigs through adjuvanted nanotechnology-based vaccination.
-
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.
-
Approaches to HIV vaccine design.
-
Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs.
-
Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition.
-
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
-
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.
-
Childhood vaccine development: an overview.
-
Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice.
-
Chimeric alphavirus vaccine candidates for chikungunya.
-
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.
-
Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques.
-
Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques.
-
Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine.
-
Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
-
Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus.
-
Cost-effectiveness of a potential vaccine for human papillomavirus.
-
Cross-Reactive Immunity Among Flaviviruses.
-
Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant.
-
Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
-
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge.
-
DNA vaccines and immunity to herpes simplex virus.
-
DNA vaccines.
-
DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.
-
Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus.
-
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
-
Determination of the cleavage site of enterovirus 71 VP0 and the effect of this cleavage on viral infectivity and assembly.
-
Development of a vaccine for the prevention of AIDS, a critical appraisal.
-
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
-
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.
-
Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
-
Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.
-
Enhanced immunity after Ad26.COV2.S vaccine breakthrough infection.
-
Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates.
-
Ensuring global access to COVID-19 vaccines.
-
Enteroviruses in the early 21st century: new manifestations and challenges.
-
Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities.
-
Evaluating human papillomavirus vaccination programs.
-
Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine.
-
Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
-
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.
-
HIV antibodies and vaccine design.
-
HIV immunization. Fresh pathways to follow.
-
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.
-
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.
-
HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting.
-
Harnessing virus tropism for dendritic cells for vaccine design.
-
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
-
Hepatitis B surface antigen could harbour the infective agent of AIDS.
-
Hepatitis B virus vaccine. An analysis of its potential use in medical workers.
-
High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.
-
Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
-
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection.
-
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
-
Immunizations for preteens.
-
Immuno-prophylaxis and -therapy of C-type oncorna viral diseases in mice and cats.
-
Immunobiology of the human immunodeficiency virus envelope and its relationship to vaccine strategies.
-
Immunotherapy for gynaecological malignancies.
-
Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.
-
Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells.
-
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
-
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
-
Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins.
-
Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
-
Induction of cytotoxic T cell responses in newborn mice by DNA immunization.
-
Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model.
-
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later.
-
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.
-
Intranasal delivery of an adjuvanted modified live porcine reproductive and respiratory syndrome virus vaccine reduces ROS production.
-
Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs.
-
Kaposi's sarcoma and hepatitis B vaccine.
-
Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
-
Liposomes as antigen delivery systems in viral immunity.
-
Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development.
-
Mammalian C-type oncorna viruses. Relationships between structural virus and cell surface antigens and their possible significance in immunological defense mechanisms.
-
Maternal immunisation to improve the health of HIV-exposed infants.
-
Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies.
-
Modified varicella-like syndrome in children previously vaccinated with live attenuated measles, mumps, rubella and varicella vaccine.
-
Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective.
-
Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
-
Murine granulocyte-macrophage colony-stimulating factor expressed from a bicistronic simian immunodeficiency virus-based integrase-defective lentiviral vector does not enhance T-cell responses in mice.
-
Mycobacterium tuberculosis whole cell lysate enhances proliferation of CD8 positive lymphocytes and nitric oxide secretion in the lungs of live porcine respiratory and reproductive syndrome virus vaccinated pigs.
-
NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection.
-
Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus.
-
Natural immunity to HIV and its possible relationship to vaccine strategies.
-
Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals.
-
Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys.
-
Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.
-
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
-
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.
-
Numerical evaluation of spray position for improved nasal drug delivery.
-
Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.
-
PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs.
-
Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.
-
Porcine reproductive and respiratory syndrome virus induces pronounced immune modulatory responses at mucosal tissues in the parental vaccine strain VR2332 infected pigs.
-
Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate.
-
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.
-
Potential leukemia virus subunit vaccines: discussion.
-
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
-
Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
-
Progress in vaccine development against SIV and HIV.
-
Progress in vaccines against AIDS.
-
Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine.
-
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
-
Prospects for a safe COVID-19 vaccine.
-
Prospects for development of a vaccine against HTLV-III-related disorders.
-
Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines.
-
Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus.
-
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
-
Recent changes in vaccination guidelines. An update on vaccines and target population initiatives.
-
Recent clinical progress in virus-based therapies for cancer.
-
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.
-
Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
-
Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.
-
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
-
Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.
-
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
-
Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy.
-
Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques.
-
Retroviral E-DNA: persistence and gene expression in nondividing immune cells.
-
RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines.
-
Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.
-
Rich countries should tithe their vaccines.
-
Role of HIV membrane in neutralization by two broadly neutralizing antibodies.
-
SIV vaccine protection of rhesus monkeys.
-
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.
-
Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization.
-
Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children.
-
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.
-
Simian immunodeficiency virus DNA vaccine trial in macaques.
-
Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines.
-
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
-
Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques.
-
Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development.
-
Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements.
-
Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.
-
Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection.
-
Technologies for global health.
-
Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
-
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.
-
The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.
-
The impact of rotavirus gastroenteritis on the family.
-
The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group.
-
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
-
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.
-
Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.
-
Toward a vaccine against AIDS: rationale and current progress.
-
Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice.
-
Understanding orthopoxvirus interference with host immune responses to inform novel vaccine design.
-
Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
-
Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection.
-
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.
-
Vaccination to Prevent Cancer.
-
Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.
-
Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.
-
Vaccine development for HIV infection.
-
Vaccine immunogenicity in injecting drug users: a systematic review.
-
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.
-
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
-
Vaccines in 2017: Closing in on a Zika virus vaccine.
-
Varicella during pregnancy. Maternal and fetal effects.
-
Varicella in a susceptible pregnant woman.
-
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
-
Virology, Epidemiology, Pathogenesis, and Control of COVID-19.
-
Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines?
-
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.
-
Keywords of People